Novartis
Leqvio
page 2 of 4
4C
79%
OF LEQVIO PATIENTS WERE FULLY ADHERENT 
1‡§ (PDC ≥0.8)
THE FIRST-IN-CLASS PCSK9 siRNA LDL-C–LOWERING THERAPY
CLAIMS CONFIRM A PATIENT RECEIVED LEQVIO. 
Evolocumab and alirocumab claims do not confi rm self-administration,
so PDC for PCSK9 mAbs may be overestimated.*
IMPORTANT SAFETY INFORMATION
Contraindication: LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in 
LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema.
INDICATION
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with 
hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
KNOW WITH LEQVIO
®
The comparison pertains only to differences in adherence or persistence as defi ned by this analysis and should not be considered a 
comparison of effi  cacy or safety. 
Limitations: The study was conducted using administrative claims data (collected for non-research purposes), with limited details on 
clinical variables and susceptibility to missing data and coding-related errors. Clinical characteristics and medications were captured during 
the 12 months prior to the initiation period; anything beyond the 12-month period was not observable. LEQVIO is HCP-administered; therefore, 
claims ensure patients received the injection, whereas evolocumab and alirocumab claims do not confi rm self-administration, thus PDC for 
PCSK9 mAbs may be overestimated.
In the ORION-10 (N=1561) study in adults with ASCVD, on top of maximally tolerated statin, LEQVIO provided:
Study design: ORION-10 (N=1561) and ORION-11 (N=1617) were multicenter, double-blind, randomized, placebo-controlled, 18-month, phase 3 trials 
in adults with established ASCVD (ORION-10 and ORION-11) or increased risk of CVD (ORION-11). Patients were taking a maximally tolerated statin 
with or without other lipid-modifying therapy and required additional LDL-C reduction. The primary effi  cacy measure was the percent change in 
LDL-C from baseline to day 510.2,4
Results were similar in patients with ASCVD in ORION-11.
LDL-C reduction 
vs placebo at month 17 
(95% CI: -56%, -49%; P<0.0001)2
52%
of patients achieved
LDL-C target <70 mg/dL 
compared with 18% of patients with 
placebo at month 173
84%
of patients achieved 
an LDL-C <55 mg/dL 
compared with 4% of patients on 
placebo at month 173
75%
Please see additional Important Safety Information on the next page and Brief Summary of Prescribing Information on adjacent page.

View this content as a flipbook by clicking here.